News | July 19, 2023
PrecisionLife identifies first detailed genetic risk factors for long COVID
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Approval to dramatically change CAR-T therapies landscape
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Subscribe To Our Newsletter & Stay Updated
